<unk> , sold under the brand name Brilinta among others, is a medication used for the prevention of stroke, heart attack and other events in people with acute coronary syndrome, meaning problems with blood supply in the coronary arteries. It acts as a platelet aggregation inhibitor by antagonising the P2Y12 receptor. The drug is produced by AstraZeneca. 90 mg tablet of Brilinta It was approved for medical use in the European Union in December 2010, and in the United States in July 2011. A reversal agent, bentracimab, is under investigation for use in major or life-threatening hemorrhage.
Ticagrelor
Clopidogrel
Ticlopidine
Prokarin
Rivaroxaban
Eptifibatide
Apixaban
Palladin